ISTH2020. Presentation: Thrombosis, bleeding, and the effect of anticoagulation on survival in critically ill patients with COVID-19 in the United States.
ISTH2020. Presentation: Incidence of venous thromboembolism in patients discharged after COVID-19 hospitalization.
ISTH2020. Presentation: Fibrinogen is citrullinated in venous thrombi and forms fragile clots with increased resistance to lysis.
International Liver Congress (ILC 2020). Presentation: The VWF/ADAMTS13 imbalance, but not global coagulation or fibrinolysis, is associated with outcome and bleeding in patients with acute liver failure.
ASH2020. Presentation: Soluble platelet agonists expand the procoagulant surface in heparin-induced thrombocytopenia.
ASH2020. Presentation: Soluble platelet agonists expand the procoagulant surface in heparin-induced thrombocytopenia.
ISTH2019. Presentation: epigenetics in hemostasis.
2018 American Society of Haematology Conference (San Francisco). Presentation: defining the molecular mechanisms through which the macrophage galactose lectin (MGL) receptor regulates von Willebrand factor clearance.
ISTH2019. Presentation: a new algorithm based on thrombin generation to assess hormone-related prothrombotic changes.
11th ECAT meeting—Leiden (Netherlands; 2018) presentation: interference of DOACs on coagulation tests.
ISTH2019. Presentation: evaluation of the predictive value of the bleeding prediction score “VTE-BLEED” for recurrent venous thromboembolism.
ISTH2019. Presentation: VWD and pregnancy—results of an International Survey.
ISTH2019. Presentation: thrombosis risk after switching oral contraceptive type.
ASH 2017 USA Presentation: Phe174-Mutated Human Factor X As Bypassing Agent to the Direct FXa Inhibitors
9th Haemostasis Update Meeting, 2018 Melbourne: Role of platelets in haemostasis and thrombosis
9th Haemostasis Update Meeting, 2018 Melbourne: Platelet function testing
XXVth Slovak-Czech conference on hemostasis and thrombosis, Martin, Slovakia, 2018: Genetic background of von Willebrand disease
XXVth Slovak-Czech conference on hemostasis and thrombosis, Martin, Slovakia, 2018: Proton pump inhibition affects the dabigatran on-treatment levels in patients with atrial fibrillation
2nd Joint Meeting of the International Society of Fibrinolysis and Proteolysis and the Plasminogen Activation Workshop, Edinburgh, UK, 2018: External blood clots are covered by a fibrin bio-film that protects against infection
IVAR VAN ASTEN
ISLH 2016 presentation: Diagnostic value of a flow cytometry based platelet function test compared with light transmission aggregometry in patients with unknown bleeding disorders.
ISTH 2017 presentation: Mortality in Patients with Intracerebral Haemorrhage Associated with Vitamin K Antagonists, Direct Oral Anticoagulants, Antiplatelets or No Antithrombotic Therapy
ISTH 2017 presentation: Neutrophil Extracellular Traps In Thrombi from Patients with Acute Ischemic Stroke
ISTH 2017 presentation: Patients with Coronary Artery Disease Have a Pathological P2Y12 Platelet Response with Heightened Procoagulant Platelet Potential
ISTH 2017 presentation: Dental Extractions on NOACs without Stopping Therapy (DENTST) Study
ISTH 2017 presentation: Choice of Anticoagulation in the Obese
ISTH SSC 2016 presentation: Blood outgrowth endothelial cells from type 3 von Willebrand disease patients display abnormal angiogenesis
ISTH SSC 2016 presentation: A novel factor VIII–nanobody fusion protein displaying prolonged half-life and hemostatic efficacy in vivo
ISTH SSC 2016 presentation: HYPATIA—A prospective randomized controlled trial of HYdroxychloroquine versus placebo during Pregnancy in women with AnTIphospholipid Antibodies
ADI J. KLIL-DRORI
2016 ASH presentation: The Risk of Major Bleeding with Low-Molecular-Weight-Heparins for Venous Thromboembolism in Dialysis Patients: The Q-VTE Study
2016 ASH presentation: Adeno-Associated Virus Mediated Gene Transfer for Hemophilia B Achieves Sustained Mean Factor IX Activity Levels of >30% without Immunosuppression
HAA 2016 presentation: Validation of plasma miR-494–3p and miR-365a-3p expression levels as indicators of thrombotic risk
DLTH 2015 presentation: Genetics of sticky platelet syndrome and fetal loss
DLTH 2015 presentation: Practical aspects of monitoring of antiplatelet therapy
DLTH 2015 presentation: Rotational thromboelastometry and monitoring of anticoagulation in pregnant women with increased risk of fetal loss
ISTH 2015 presentation: Venous thromboembolism occurring during adolescence: is it preventable?
ISTH 2015 presentation: DNA in plasma indicates disease extent and predicts mortality in patients with venous thromboembolism
JONATHAN M. COUTINHO
ISTH 2015 presentation: Is anemia a risk factor for cerebral venous thrombosis?
DR. ANDREAS TIEDE
ASH presentation: Prognostic Parameters For Remission Of and Survival In Acquired Hemophilia A: Results Of The GTH-AH 01/2010 Multicenter Study
DR. WENDY LIM
ASH presentation: Antiphospholipid Syndrome
DR. RITEN KUMAR
WFH presentation: Exercise increases FVIII, von Willebrand factor and platelet counts in boys with hemophilia A and B: preliminary findings of the SickKids hemophilia exercise study
DR. MARIA ELISA MANCUSO
WFH presentation: Thrombin generation assay in hemophilic patients with or without inhibitor undergoing orthopedic surgery
DR. SUSANA NOBRE FERNANDES
WFH presentation: Economic impact of individualized prophylaxis approach on a severe hemophilia young adult cohort
DR. COEN MAAS
ISLH presentation: Detection of Plasma Contact System Activation in Thrombotic
DR. VIVIAN XIAOYAN DU
ASH presentation entitled “Binding of erythrocyte ICAM-4 to the platelet activated integrin αIIbβ3 leads to a direct erythrocyte-platelet adhesion under venous flow shear rate”
DR. ANDREW YEE
ASH presentation entitled “Partial in vivo FVIII stabilization by VWF fragments”
DR. SARAH O’BRIEN
ASH presentations, one being related to use of bivalirudin in children with venous thromboembolism and the other assessing von Willebrand Disease in adolescents
DR. VERONICA FLOOD
ASH presentation on von Willebrand Disease testing
Mayo Coagulation Quality presentation on issues related to verification and assignment of International Sensitivity Index (ISI) values for determination of International Normalized Ratio (INR) values across different laboratories in a large network
Presentation at a large Australian regional meeting comprising a conjoint scientific meeting of the Haematology Society of Australia and New Zealand, Australian and New Zealand Society of Blood Transfusion,and Australasian Society of Thrombosis and Haemostasis
DR. ROMARIC LACROIX
Aix-Marseille University, France. For presentations delivered at the XXIII ISTH Congress in Kyoto, Japan, 2011
DR. TIM GANDERTON
Presentation at HAA2011 on his recently awarded Ph.D. topic, namely the “Mechanism of Lateral Self-Association of Von Willebrand Factor,” the data from which he recently published in the journal Blood.
PH.D. CANDIDATE BRAD McEWEN
Presentation at HAA2011, on the topic of “Low Dose Omega-3 on Fibrin and Thrombin Generation in Healthy Volunteers and Patients with Cardiovascular Disease.”
DR. VIVIEN CHEN
Oral presentations at HAA2012, including a detailed presentation on insights into thrombus initiation gained through intravital imaging.
DR. NEIL GOLDENBERG
Spoke at ISTH, and currently holds several clinical and academic positions, although in essence is a pediatric hematologist interested in pediatric hypercoagulability. Dr. Goldenberg has most recently developed a new global hemostasis assay (the clot formation and lysis assay, CloFAL).
DR. JOSEPH E. ITALIANO
Presentations at ISTH, including a talk in the Platelet Symposium in which he described the outstanding results of his work on megakaryocyte and the formation of platelets, as well as the role of platelets in angiogenesis.
Dr. Adam Cuker (University of Pennsylvania)
Presentation at the 2010 American Society of Hematology meeting on immune thrombocytopenia (ITP), as well as his work related to a novel expert-based clinical scoring model for heparin-induced thrombocytopenia (HIT).
Dr. Jayandharan Giridhara Rao (Christian Medical College, Vellore, Tamil Nadu)
Papers on quality assurance in genetic testing for disorders of hemostasis, and the role of new technologies in hemophilia diagnosis and therapy at the Hemophilia World Congress in Argentina in 2010.
Dr. Timea Szanto (Helsinki University Central Hospital)
Presentation on platelet function and von Willebrand disease (VWD) at the Nordic Coagulation Meeting in 2010.
Dr. Birgitta Salmela (Helsinki University Central Hospital)
Paper on laboratory monitoring of new anticoagulants presented at the Nordic Coagulation Meeting in 2010.
Dr. Pia Riittaa-Maria Siljander (University of Helsinki)
Presentation on platelet-derived micro-particles given at the Nordic Coagulation Meeting in 2010.
Dr. Salley Pels
Dr. Salley Pels was nominated for her award as a result of an oral presentation she gave at the recent American Society for Hematology (ASH) 51st Annual Meeting held in December 2009, on the use of intravenous immune globulin in immune thrombocytopenia. Dr. Pels received her undergraduate degree in Chemistry at the Johns Hopkins University. She then went on to the University of Vermont College of Medicine for her Medical degree. Her training continued at Yale University and Yale-New Haven Children's Hospital, during a residency in General Pediatrics. Dr. Pels is currently nearing the end of a fellowship in Pediatric Hematology and Oncology at this facility. She has planned to complete an additional fellowship year in Clinical Hemostasis and Thrombosis, through a two-year award given by the National Hemophilia Foundation and Baxter.
Dr. Pels was granted several other awards in 2009, the Hemophilia and Thrombosis Research Society Young Investigators' Travel Award and the ASH Travel Award. Dr. Pels will prepare a paper on Immune Thrombocytopenia, the topic of her ASH presentation, for Seminars in Thrombosis and Hemostasis that is expected to appear in press sometime in 2011. We congratulate Dr. Pels on her award, look forward to her contribution to this journal and wish her the best of success for her future career.
Dr. Willem M. Lijfering
Dr. Willem M. Lijfering was also nominated for his award as a result of an oral presentation he gave at the same meeting, the recent American Society for Hematology (ASH) 51st Annual Meeting held in December 2009. Dr. Lijfering's topic was on the risk of venous thrombosis as related to an increase in body mass index and as mediated by factor VIII induced activated protein C resistance. Dr. Lijfering was born in 1978 and was trained in Europe. Dr. Lijfering was awarded his MD in May 2004, and his first clinical experience was obtained in Australia where he worked as a resident medical officer at the Mount Isa Base Hospital.
From 2005 till 2009, he worked as an internist in training in the UMCG, Groningen, the Netherlands. He started a PhD in 2005, which was awarded in 2008, and began his training as a Clinical Epidemiologist in 2009. Dr. Lijfering has had a very successful career to date, and from 2006 onwards, has presented or supervised more than 24 communications to international congresses of which 11 were oral communications. He has managed to publish 11 articles over the past year, all related to venous thrombosis, including several in high impact journals such as Blood and Circulation. Willem Lijfering has a particular and long-term interest in arterial and venous thrombosis, and has agreed to prepare a paper on the topic of his ASH presentation for Seminars in Thrombosis and Hemostasis that is also expected to appear in press sometime in 2011. We congratulate Dr. Lijfering on his award, look forward to his contribution to this journal and wish him the best of success for his future career.
Learn more about the Eberhard F Mammen awards by selecting the following links: